NYSE: CL · Household Products
Colgate-Palmolive
Colgate-Palmolive sells oral care (Colgate toothpaste and toothbrushes), personal care (Palmolive, Softsoap, Irish Spring, Speed Stick, EltaMD, Filorga), and home care (Ajax, Fabuloso, Suavitel) products, plus Hill's pet food. Oral care was 44% of 2025 net sales, personal care 17%, home care 16%, and Hill's Pet Nutrition 23%. About two-thirds of revenue comes from outside the U.S., and its toothpaste held a 41.3% global market share in the first half of 2026. FY2025 net sales were $20.4 billion and net income $2.13 billion, reduced by a $919 million impairment mainly on the Filorga skin-care brand.
Last updated
Analysis last edited: November 6, 2026 · Financial data fetched: October 17, 2026 10:06 (SEC EDGAR) · Source 10-K filed: February 23, 2026
Built on10-K FY2025 · filed 2026-02-2310-Q (quarter ended 2026-09-30) · filed 2026-10-30
Next update expectedAfter FY2026’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.
01
At a glanceFrom SEC data
Eight headline measures, each placed among the companies covered on this site.
- Revenue growthCAGRSmooths out year-to-year swings into "grew X% a year on average." Makes growth pace comparable across companies of very different sizes.
- 4.4%
- Operating marginOperating marginHow many cents of operating profit are left per dollar of revenue. Reflects pricing power and cost structure.
- 16.2%
- ROIC minus WACCROIC − WACC spreadThe difference between ROIC and WACC. Consistently positive implies value creation; consistently negative implies value destruction.
- +22.9 pts
- Net debt ÷ EBITDAEBITDAOperating income with D&A added back. A rough proxy for cash-generating power that’s less distorted by capital intensity, depreciation method, or financing/tax differences than net income.
- 1.6x
- Cash conversionOperating CF ÷ net income (cash conversion)How much of reported profit shows up as actual cash. 1x or higher means profit is backed by cash.
- 1.97x
- Dividend raisesDividend per shareTotal annual dividend paid per share (sum of all declared payments for the year).
- 5 of 5
- P/E todayP/EShare price ÷ EPS — how many years of current earnings the stock price represents. This site uses the period-end figure as reported in the filing.
- 38.3x
- Betaβ (beta)How much a stock moves, on average, for a 1% move in the overall market. Above 1 means more volatile than the market, which raises the return shareholders require. This site computes it from about 2.5 years (roughly 130 weeks) of weekly returns, built from Yahoo Finance daily prices, regressed against an S&P 500 ETF (SPY) as the market proxy, then applies the well-known long-run mean-reversion adjustment (0.67 × β + 0.33) as the WACC default.
- 0.40
Higher than 19% of 372 non-financial companies
Average yearly growth over the years shown
Higher than 41% of 311 non-financial companies
Latest fiscal year (FY2025)
Higher than 90% of 311 non-financial companies
Return on capital above (or below) its estimated cost
Higher than 47% of 304 non-financial companies
Below 0 means more cash than debt
Higher than 72% of 349 non-financial companies
Operating cash flow ÷ net income
Years the dividend per share rose, of the last 5
Latest close 2026-11-04; trailing 12 months to 2026-09-30
Above 1 = moves more than the market
Each marker shows where this company sits among the non-financial companies covered on this site, not all listed companies (left = lowest, right = highest). A high position is not automatically good — for net debt ÷ EBITDA, higher means more debt. Details and formulas are in the sections below and in How to read this.
02
Valuation todayFrom SEC data
Price-based measures at the latest close, next to the same measures at the last fiscal year-end.
Share price$98.19close on 2026-11-04
Market cap$78.67B
- P/EP/EShare price ÷ EPS — how many years of current earnings the stock price represents. This site uses the period-end figure as reported in the filing. today
- 38.3x
- P/BP/BShare price ÷ book value per share. Below 1x means the market values the company below its accounting net worth. This site uses the closing price nearest the fiscal year-end and highlights sub-1x readings. today
- 1,456.9x
- EV/EBITDAEV/EBITDAEnterprise value (≈ market cap + interest-bearing debt − cash) as a multiple of EBITDA — roughly, "how many years of EBITDA to buy the whole company." Lower is generally viewed as cheaper, and it’s more comparable than P/E across companies with different debt loads or depreciation policies. This site excludes noncontrolling interests from the EV calculation. today
- 21.6x
- FCF yieldFree cash flow (FCF)Operating CF minus capital expenditures — cash generated by the business after funding its own investment, available for dividends, buybacks, acquisitions, or debt paydown. Acquisitions and securities purchases (also in investing CF) are not subtracted, so FCF can be positive in a year when total investing CF exceeds operating CF. today
- 4.6%
- Dividend yieldDividend per shareTotal annual dividend paid per share (sum of all declared payments for the year). today
- 2.1%
At FY2025 year-end: 30.1x
Earnings: trailing 12 months to 2026-09-30
At FY2025 year-end: 1,172.5x
Book value at FY2025 year-end
At FY2025 year-end: 17.8x
EBITDA for FY2025
At FY2025 year-end: 5.7%
Free cash flow for FY2025
Dividends per share for FY2025
“Today” uses the latest closing price (2026-11-04, Yahoo Finance daily closing prices) and shares outstanding at the last fiscal year-end. The rest of this page — including the financial table and ROIC vs. WACC — uses fiscal year-end prices. These are reference figures, not a judgment of whether the stock is cheap or expensive.
03
What changed since last earningsFrom SEC data
The latest reported quarter against the same quarter a year earlier, the balance sheet against the previous quarter-end, and what management said in its latest earnings release.
Quarter ended Sep 30, 2026.
- Revenue$5.13B → $5.37B (vs. a year earlier)↑ +4.6%$5.13B → $5.37B (vs. a year earlier)
- Operating margin20.6% → 20.3% (vs. a year earlier)↓ −0.4 pts20.6% → 20.3% (vs. a year earlier)
- Net income$735M → $751M (vs. a year earlier)↑ +2.2%$735M → $751M (vs. a year earlier)
- Diluted EPS$0.91 → $0.94 (vs. a year earlier)↑ +3.3%$0.91 → $0.94 (vs. a year earlier)
- Cash$1.37B → $1.53B (vs. previous quarter-end)↑ +11.5%$1.37B → $1.53B (vs. previous quarter-end)
- Long-term debt$7.82B → $7.18B (vs. previous quarter-end)↓ −8.2%$7.82B → $7.18B (vs. previous quarter-end)
Source: Form 10-Q ↗ (SEC XBRL). Long-term debt is the tagged long-term debt figure and leaves out short-term borrowings.
From the earnings release of Oct 30, 2026.
Management outlook ↔ Narrowed
Narrowed 2026 sales guidance and raised gross margin and Base Business EPS guidance. Source sentence
The Company narrowed its sales guidance and raised its gross profit margin and Base Business earnings per share guidance for full year 2026
Key changes
Now expects net sales up 4%–5%, versus 2%–6% before. Source sentence
The Company now expects net sales to be up 4% to 5% (versus 2% to 6% previously), including a low-single-digit positive impact from foreign exchange.
Organic sales up 3.6%. Source sentence
Organic sales* increased 3.6%, including a 0.2% negative impact from lower private label pet food sales
Gross margin up 80 basis points to 60.2%. Source sentence
GAAP Gross profit margin increased 80 basis points to 60.2%;
Written by AI. A line appears only if its figures and direction match the quoted sentence, which an automatic check confirms. Companies' outlooks are their own and may not be met. Read the release ↗
04
Company profileFrom SEC dataShow
- Legal name
- COLGATE PALMOLIVE CO
- Headquarters
- NEW YORK, NY
- Incorporated in
- Delaware
- Fiscal year end
- 12/31
- Exchange & ticker
- NYSE: CL
- Industry
- Household Products
- CIK
- 21665
Workforce (as of FY2025 year-end)
Employees
33,600
Source: Form 10-K (FY2025) cover page and business description
05
Earnings calendarFrom SEC dataShow
When the company reports each quarter: the quarter-end date, the day results were released, and when the 10-Q or 10-K was filed.
Next report
Q4 FY2026
Quarter end: December 2026. In past years, Q4 results were released 26–31 days after quarter end (Jan 30, 2026; Jan 31, 2025; Jan 26, 2024). No date has been announced in the sources this site uses.
Reporting pattern
- Fiscal year ends around December 31.
- Reports four times a year: three quarterly reports (10-Q) and an annual report (10-K) for Q4.
- Earnings releases came 25–32 days after quarter end over the last 12 quarters.
| Quarter | Quarter ended | Earnings release (8-K) | Report filed (10-Q / 10-K) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | Oct 30, 2026 (+30 days) | Oct 30, 2026 10-Q (+30 days) |
| Q2 FY2026 | Jun 30, 2026 | Jul 31, 2026 (+31 days) | Jul 31, 2026 10-Q (+31 days) |
| Q1 FY2026 | Mar 31, 2026 | May 1, 2026 (+31 days) | May 1, 2026 10-Q (+31 days) |
| Q4 FY2025 | Dec 31, 2025 | Jan 30, 2026 (+30 days) | Feb 23, 2026 10-K (+54 days) |
| Q3 FY2025 | Sep 30, 2025 | Oct 31, 2025 (+31 days) | Oct 31, 2025 10-Q (+31 days) |
| Q2 FY2025 | Jun 30, 2025 | Aug 1, 2025 (+32 days) | Aug 1, 2025 10-Q (+32 days) |
| Q1 FY2025 | Mar 31, 2025 | Apr 25, 2025 (+25 days) | Apr 25, 2025 10-Q (+25 days) |
| Q4 FY2024 | Dec 31, 2024 | Jan 31, 2025 (+31 days) | Feb 13, 2025 10-K (+44 days) |
| Q3 FY2024 | Sep 30, 2024 | — | Oct 25, 2024 10-Q (+25 days) |
| Q2 FY2024 | Jun 30, 2024 | Jul 26, 2024 (+26 days) | Jul 26, 2024 10-Q (+26 days) |
| Q1 FY2024 | Mar 31, 2024 | Apr 26, 2024 (+26 days) | Apr 26, 2024 10-Q (+26 days) |
| Q4 FY2023 | Dec 31, 2023 | Jan 26, 2024 (+26 days) | Feb 15, 2024 10-K (+46 days) |
Source: SEC EDGAR filing history. Release dates are the dates the earnings release was furnished to the SEC on Form 8-K (Item 2.02), which is normally the day results are announced. For a quarter whose 10-Q or 10-K isn’t filed yet, the date is the latest Item 2.02 8-K since the previous report, which may be a preliminary or other results-related update. Fiscal years are labeled by the calendar year in which they end.
06
Flagship products & servicesSite analysis
Oral Care
Toothpaste, toothbrushes, mouthwash
Examples: Colgate, Darlie, elmex, hello, meridol, Tom's of Maine
44% of net sales; global leader in toothpaste and manual toothbrushes.
Personal Care
Soaps, deodorants, skin health
Examples: Palmolive, Softsoap, Irish Spring, Speed Stick, EltaMD, Filorga, PCA SKIN
17% of net sales; global leader in liquid hand soap.
Home Care
Cleaners and fabric care
Examples: Ajax, Fabuloso, Murphy, Suavitel
16% of net sales.
Pet Nutrition
Hill's
Examples: Science Diet, Prescription Diet, Prime100
23% of net sales.
Descriptions and shares are from the FY2025 Form 10-K's Item 1.
U.S., worldwide and country/regional share of flagship products/services
Only shares the company itself states (in its filings or press releases, sometimes citing a research firm) are shown. Scope and timing vary by figure — treat these as approximate.
Toothpaste (Colgate)
Global toothpaste, value share (Nielsen and internal estimates)
U.S. share
—
Not disclosedWorldwide share
41.4%
Company-disclosedYear-to-date through Q3 2026; full year 2025 was 41.3%.
Manual toothbrushes
Global manual toothbrushes, value share
U.S. share
—
Not disclosedWorldwide share
33.1%
Company-disclosedYear-to-date through Q3 2026; full year 2025 was 32.4%.
Liquid hand soap (Palmolive, Protex, Softsoap)
Worldwide
U.S. share
—
Not disclosedWorldwide share
Global leader
Company-disclosedThe 10-K cites "global leadership in liquid hand soap" based on market share data; no percentage is given.
Sources:
Shares are value shares in the countries where Colgate buys data, mainly from Nielsen, and exclude some channels such as e-commerce.
07
Recent strategic focusSite analysis
Restructuring and 2026 developments, from 8-Ks.
Bigger productivity program
In April 2026 the board expanded the Strategic Growth and Productivity Program; expected cumulative pre-tax charges rose to $350–550M from $200–300M.
Source: 8-K filed 2026-05-01 (Item 2.05)
Segment realignment
From Q1 2026, Europe, Africa/Eurasia (excluding Russia and Belarus), and Skin Health form a new Europe, Middle East and Africa segment.
Source: 8-K filed 2026-03-17
Q3 2026
Net sales rose 4.6% to $5.37B (organic 3.6%), GAAP EPS rose 3% to $0.94 and Base Business EPS 7% to $0.97. Colgate narrowed its 2026 sales guidance and raised its gross margin and Base Business EPS guidance.
Source: 8-K filed 2026-10-30 (Exhibit 99)
Prime100 acquisition
Colgate bought the owner of Prime100 fresh pet food in Australia for about $301M in April 2025.
Source: Form 10-K (FY2025) MD&A
Capex ÷ D&A (FY2025)
0.90x
Roughly matches depreciation — mostly maintenance/replacement
formulacapital expenditures ÷ depreciation & amortization
e.g.$564M ÷ $630M = 0.90x
termsCapital expenditures (capex) · Depreciation & amortization (D&A)
R&D-to-revenue ratio (FY2025)
1.8%
formularesearch & development expense ÷ revenue × 100
e.g.$366M ÷ $20,382M × 100 = 1.8%
M&A spend (6-year total)
$1.46B
Latest year: $293M
Cash-flow-statement spending on acquisitions, net of cash acquired
Where the money goes, over time
Unit: $M. Capex went from $409M in FY2020 to $564M in FY2025
- Capex
- R&D
- M&A spend
formulacapital expenditures ÷ depreciation & amortization
termsCapital expenditures (capex) · Depreciation & amortization (D&A)
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-23
08
Key figures at a glanceFrom SEC data
FY2020–FY2025, 6 years.
Revenue (FY2025)
$20.38B
As reported in the 10-K
Revenue CAGR (5 years)
+4.4%
formula(last-period revenue ÷ first-period revenue) ^ (1 ÷ years) − 1
e.g.($20,382M ÷ $16,471M) ^ (1÷5) − 1 = 4.4%
termsCAGR · ^ (exponent) · Revenue (net sales)
Operating margin (FY2025)
16.2%▼caution
-7.4pt vs. 5 years ago
formulaoperating income ÷ revenue × 100
e.g.$3,306M ÷ $20,382M × 100 = 16.2%
ROE (FY2025)
1603.0%▲favorable
6-year average: 633.1%
As reported in the 10-K
P/B (FY2025 end)
1,172.48x
formulafiscal year-end closing price ÷ book value per share
e.g.$79.02 ÷ $0.07 = 1172.48x
Period-end (fiscal year-end) value, not today's P/B
EV/EBITDA (FY2025 end)
17.8x
formula(market cap + interest-bearing debt − cash and equivalents) ÷ (operating income + depreciation & amortization)
e.g.($63,314M + $7,839M − $1,288M) ÷ ($3,306M + $630M) = 17.8x
termsEV/EBITDA · Market capitalization · Interest-bearing debt · EBITDA · Depreciation & amortization (D&A)
Period-end (fiscal year-end) value, not today's multiple
- ―
Revenue grew +4.4% a year over 5 years (modest growth)
From $16.47B in FY2020 to $20.38B in FY2025. The annualized rate (CAGR) makes it possible to compare growth pace across companies of different sizes.
- ▼
Operating margin declined: 23.6% → 16.2%
How much operating profit is left per $100 of revenue. It moved -7.4 points over 5 years — pricing power, cost control, and product mix all show up here.
- ▼
Equity ratio is 0.3% (relatively heavy reliance on debt)
The share of total assets funded by equity rather than debt. 50%+ is often read as low bankruptcy risk, though the right level varies by industry (real estate and leasing run lower, for instance).
- ▲
Free cash flow was positive in 6 of 6 years
Operating cash flow minus capital expenditures: the cash left over after funding the business’s own investment, available for dividends, buybacks, acquisitions, or debt paydown. A negative year can mean heavy investment, or weak core earnings — worth distinguishing.
- ▲
ROE averaged 633.1% over 6 years (latest: 1603.0%)
How much profit was generated on shareholders’ equity. Roughly 10%+ is often cited as solid for a U.S. company, though this varies a lot by industry and capital intensity.
09
Business modelSite analysis
Business Model Canvas
The whole company in nine blocks. Left side: how it delivers (partners, activities, resources, costs). Right side: who it serves and how it earns. Every entry comes from the company’s filings shown on this page.
08 · who helps
Key partners
No partners or suppliers named in the filings.
07 · what it does
Key activities
Oral, Personal and Home Care
Science-led product innovation- Advertising and promotion (increasingly digital)
Hill's Pet Nutrition
Developing nutrition and therapeutic diets
06 · what it draws on
Key resources
Oral, Personal and Home Care
Raw and packaging materials from multiple suppliers- Plants worldwide
Hill's Pet Nutrition
Pet food plants- Veterinary relationships
02 · why customers buy
Value propositions
- Toothpaste, toothbrushes, personal and home care and Hill's specialty pet food, sold in over 200 countries.
04 · how it keeps them
Customer relationships
- Hill's sold through veterinarians; ongoing retailer relationships.
03 · how it reaches them
Channels
- Direct sales force at operating subsidiaries, plus distributors and brokers; Hill's through pet supply retailers, veterinarians and e-commerce.
01 · who it serves
Customer segments
Oral, Personal and Home Care
Retailers (Walmart ~11% of sales), wholesalers, distributors, eCommerceHill's Pet Nutrition
Pet supply retailers, veterinarians, eCommerce retailers
09 · where money goes
Cost structure
FY2025, share of revenue ($20.38B)
- Cost of revenue39.9%
- Research & development1.8%
- Selling, general & administrative38.8%
- Other operating costs3.3%
Operating profit left: 16.2% of revenue. Depreciation & amortization (inside the costs above): $630M. Capital spending: $564M.
Source: Form 10-K income statement and cash-flow statement (SEC XBRL).
05 · how money comes in
Revenue streams
Oral, Personal and Home Care
Product salesHill's Pet Nutrition
Product sales
Value propositions, channels and customer relationships: Form 10-K (FY2025)
Oral, Personal and Home Care
Toothpaste, toothbrushes, mouthwash, soaps, deodorants, skin health, dishwashing liquids, cleaners, and fabric conditioners sold in more than 200 countries through retailers, wholesalers, and distributors.
01 what it draws on
Inputs & resources
- Raw and packaging materials from multiple suppliers
- Plants worldwide
02 what it does
Activities
- Science-led product innovation
- Advertising and promotion (increasingly digital)
03 who it serves
Customers
- Retailers (Walmart ~11% of sales), wholesalers, distributors, eCommerce
04 how money comes in
How it earns
- Product sales
Oral, Personal and Home Care: how it makes money
- Net sales $15.8B and operating profit $3.96B in FY2025.
- Latin America ($4.8B sales, $1.41B operating profit) is the largest region.
Hill's Pet Nutrition
Specialty pet food for dogs and cats under Hill's Science Diet, Hill's Prescription Diet, and Prime100, sold in over 80 countries.
01 what it draws on
Inputs & resources
- Pet food plants
- Veterinary relationships
02 what it does
Activities
- Developing nutrition and therapeutic diets
03 who it serves
Customers
- Pet supply retailers, veterinarians, eCommerce retailers
04 how money comes in
How it earns
- Product sales
Hill's Pet Nutrition: how it makes money
- Net sales $4.6B and operating profit $1.06B in FY2025.
- Added Prime100 fresh pet food in Australia (April 2025).
Government & regulation around the business
Non-market factors from the company’s filings: what governments and regulators fund, buy, set, approve or restrict, and which part of the flow above each one touches.
Colgate faces sanctions laws and ingredient scrutiny.
Trade & export rules
Tariffs and trade rules
Subject to U.S. sanctions laws.
Constrains the businessTouches: Inputs & resourcesSource: Form 10-K (FY2025)
Approvals & licenses
Ingredient reviews
Regulators are reviewing ingredients such as fluoride.
Constrains the businessTouches: ActivitiesSource: Form 10-K (FY2025)
Revenue by segment (FY2025)
Unit: $M — bar length = revenue, (%) = share of total company revenue, margin = segment profit ÷ segment revenue × 100
North America (OPHC)
4,045 (20%)profit 784 · margin 19.4%
Latin America (OPHC)
4,776 (23%)profit 1,411 · margin 29.5%
Europe (OPHC)
2,962 (15%)profit 748 · margin 25.3%
Asia Pacific (OPHC)
2,814 (14%)profit 760 · margin 27.0%
Africa/Eurasia (OPHC)
1,172 (6%)profit 255 · margin 21.8%
Hill's Pet Nutrition
4,613 (23%)profit 1,064 · margin 23.1%
Source: Form 10-K (FY2025) — Note 14, Segment Information OPHC = Oral, Personal and Home Care. Profit is segment operating profit; Corporate (−$1.72B, including the $919M impairment) is excluded. From 2026 Europe and Africa/Eurasia are combined into Europe, Middle East and Africa.
10
Contract structureSite analysisShow
Short-term or spot sales carry different earnings quality than long-term or auto-renewing contracts — this shows how the company actually contracts with its customers.
Colgate sells to retailers and distributors; Walmart and its affiliates were about 11% of net sales in 2023–2025. No single raw or packaging material is material to the business.
Walmart
About 11% of net sales
No other customer above 10%.
Source: Form 10-K (FY2025) — Item 1
11
Customers & suppliersSite analysis
Who the company sells to and buys from. Companies rarely name either, so named counterparties come only from the company's own filings and press releases; otherwise this lists the concentration figures the 10-K discloses.
Customers
Retailers, wholesalers, distributors, pet supply retailers, veterinarians, and eCommerce retailers.
Named by the company
- Walmart — About 11% of net sales in 2023–2025.Form 10-K (FY2025) — Item 1 and Note 14
Suppliers
Raw and packaging material suppliers.
Named by the company
None named in the 10-K or the company’s press releases.
What the filings disclose
- Most raw and packaging materials are available from several sources; no single material or supplier is significant. (Form 10-K (FY2025), Item 1)
12
Competitors & peersSite analysis
Competitors the 10-K names, and the peer group the company itself chose in its proxy statement. Nothing here is this site's own pick.
Colgate's 10-K describes vigorous competition from multinational and local competitors and private label but does not name them; its proxy names a comparison group of consumer goods companies.
Competitors named in the 10-K
Colgate's 10-K doesn't name competitors.
Peer group the company chose
2025 compensation Comparison Group, from the proxy statement. Peers are companies the board considers comparable — for example when setting executive pay — not necessarily direct competitors.
14 fast-moving consumer goods companies with global brands; Kellanova was removed after its acquisition by Mars.
- Church & Dwightsite ↗
- Haleonsite ↗
- PepsiCosite ↗
- Cloroxsite ↗
- Kenvuesite ↗
- Procter & Gamblesite ↗
- Coca-Cola Companysite ↗
- Kimberly-Clarksite ↗
- Reckitt Benckisersite ↗
- Estée Lauder Companiessite ↗
- Kraft Heinzsite ↗
- Unileversite ↗
- General Millssite ↗
- Mondelez Internationalsite ↗
Company names link to this site’s analysis where one exists; “site ↗” opens the company’s own website.
13
M&A historySite analysisShow
Companies acquired over the last five years, plus older large acquisitions that still anchor a current business — what each was bought to do, and what happened afterward. From the 10-K, 8-Ks, and the company's press releases.
Colgate makes bolt-on acquisitions, mainly in skin health and pet nutrition.
Cash spent on acquisitions, FY2020–FY2025: $1.46B
Apr 2025
Care TopCo (Prime100)
AU$471M (about $301M)
Fresh pet food business in Australia.
- Stated purpose (company)
- Entry for Hill's into the fast-growing fresh pet food category in Australia.
14
Six years of financialsFrom SEC data
Each chart's axis holds a single unit (never mixing dollars, %, and $/share). The table's per-period header links to the filing the numbers came from.
Revenue over time
Unit: $M
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-23
Profit over time (operating → net)
Unit: $M
- Operating income
- Pretax income
- Net income
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-23
Margins over time
Unit: %
- Operating margin
- Net margin
formulaoperating income ÷ revenue × 100
formulanet income attributable to the company ÷ revenue × 100
Cash flow over time
Unit: $M (below zero = cash went out)
- Operating CF
- Investing CF
- Free CF
formulacash flow from operations − capital expenditures
termsFree cash flow (FCF) · Cash flow from operations (operating CF) · Capital expenditures (capex)
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-23
Financial stability & capital efficiency
Unit: %
- Equity ratio
- ROE
formulatotal equity ÷ total assets × 100 (as reported in the 10-K)
termsStockholders’ equity · Total assets
formulanet income ÷ average equity (beginning + ending, ÷2) × 100 (as reported in the 10-K)
termsNet income (attributable to the company) · Stockholders’ equity
Earnings per share (EPS) and dividend per share
Unit: $
- EPS
- Dividend per share
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-23
| Line item | FY202010-K on EDGAR ↗ | FY202110-K on EDGAR ↗ | FY202210-K on EDGAR ↗ | FY202310-K on EDGAR ↗ | FY202410-K on EDGAR ↗ | FY202510-K on EDGAR ↗ |
|---|---|---|---|---|---|---|
| Income statement ($M) | ||||||
| Revenue | 16,471 | 17,421 | 17,967 | 19,457 | 20,101 | 20,382 |
| Operating income | 3,885 | 3,332 | 2,893 | 3,984 | 4,268 | 3,306 |
| Pretax income | 3,647 | 3,087 | 2,660 | 3,392 | 3,956 | 3,059 |
| Net income (attributable) | 2,695 | 2,166 | 1,785 | 2,300 | 2,889 | 2,132 |
| Revenue growthcalc(this year’s revenue − last year’s revenue) ÷ last year’s revenue × 100 | — | 5.8% | 3.1% | 8.3% | 3.3% | 1.4% |
| Operating margincalcoperating income ÷ revenue × 100 | 23.6% | 19.1% | 16.1% | 20.5% | 21.2% | 16.2% |
| Net margincalcnet income attributable to the company ÷ revenue × 100 | 16.4% | 12.4% | 9.9% | 11.8% | 14.4% | 10.5% |
| Balance sheet ($M) | ||||||
| Total assets | 15,920 | 15,040 | 15,731 | 16,393 | 16,046 | 16,330 |
| Total equity | 1,101 | 971 | 806 | 957 | 544 | 365 |
| Interest-bearing debtSum of short- and long-term borrowings, notes/bonds payable | 7,343 | 7,206 | 8,755 | 8,239 | 7,941 | 7,839 |
| Equity ratio | 4.7% | 4.0% | 2.5% | 3.7% | 1.3% | 0.3% |
| ROE | 362.7% | 320.4% | 353.5% | 455.4% | 703.8% | 1603.0% |
| Cash flow ($M) | ||||||
| Operating CF | 3,719 | 3,325 | 2,556 | 3,745 | 4,107 | 4,198 |
| Investing CF | -779 | -592 | -1,601 | -742 | -534 | -817 |
| Financing CF | -2,919 | -2,774 | -952 | -2,793 | -3,389 | -3,256 |
| Free cash flowcalccash flow from operations − capital expenditures | 3,310 | 2,758 | 1,860 | 3,040 | 3,546 | 3,634 |
| Cash and equivalents | 888 | 832 | 775 | 966 | 1,096 | 1,288 |
| Per share & other | ||||||
| EPS ($) | 3.14 | 2.55 | 2.13 | 2.77 | 3.51 | 2.63 |
| BVPS ($) | 0.87 | 0.72 | 0.48 | 0.74 | 0.26 | 0.07 |
| Dividend per share ($) | 1.75 | 1.79 | 1.86 | 1.91 | 1.98 | 2.06 |
| Payout ratiocalcdividend per share ÷ diluted EPS × 100 | 55.7% | 70.2% | 87.3% | 69.0% | 56.4% | 78.3% |
| P/E (x) | 27.2 | 33.5 | 37.0 | 28.8 | 25.9 | 30.1 |
| EV/EBITDA (x)calc(market cap + interest-bearing debt − cash and equivalents) ÷ (operating income + depreciation & amortization) | 17.9 | 20.1 | 21.3 | 16.0 | 16.6 | 17.8 |
| P/B (x)calcfiscal year-end closing price ÷ book value per share | 97.81 | 117.78 | 163.12 | 107.51 | 348.45 | 1,172.48 |
P/B and EV/EBITDA use each period’s period-end (fiscal year-end) figures, not the current share price. Figures without a "calc" tag are as reported in the Form 10-K (the consolidated financial statements and, for older years, earlier 10-Ks), pulled automatically from SEC EDGAR. Where a later filing restated a prior period, the restated figure is used.
Last 8 quarters
Three-month figures from 10-Q filings. Change is versus the same quarter a year earlier. Newest quarter on top.
| Quarter ended | Revenue | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|
| 2026-09-30 | $5.37B+4.6% | $1.09B+2.7% | $751M+2.2% | $0.94 |
| 2026-06-30 | $5.36B+4.9% | $1.02B-5.9% | $693M-6.7% | $0.86 |
| 2026-03-31 | $5.32B+8.4% | $964M-10.4% | $646M-6.4% | $0.80 |
| 2025-12-31 † | $5.23B+5.8% | $91M-91.4% | −$36M-104.9% | — |
| 2025-09-30 | $5.13B | $1.06B | $735M | $0.91 |
| 2025-06-30 | $5.11B | $1.08B | $743M | $0.91 |
| 2025-03-31 | $4.91B | $1.08B | $690M | $0.85 |
| 2024-12-31 † | $4.95B | $1.06B | $738M | — |
† Fourth quarter = the 10-K’s annual figure minus the first three quarters; quarterly EPS isn’t derived this way because share counts change during the year.
15
Is ROIC above WACC?From SEC data
ROIC (the return on money invested in the business) above WACC (the cost of raising that money) means the company is creating value. WACC is an estimate, so its assumptions can be adjusted below.
ROIC (FY2025)
29.5%
formulaoperating income × (1 − tax rate) ÷ invested capital × 100 *invested capital = interest-bearing debt + total equity (average of beginning/ending)
e.g.$3,306M × (1 − 25.5%) ÷ $8,345M × 100 = 29.5%
termsOperating income · Effective tax rate · Invested capital · Interest-bearing debt · Total equity
WACC (this site’s estimate)
6.64%
formulacost of equity × equity weight + cost of debt × (1 − tax rate) × debt weight
e.g.Equity weight: $63.31B ÷ ($63.31B + $7.84B) = 89.0%
e.g.Debt weight: $7.84B ÷ ($63.31B + $7.84B) = 11.0%
e.g.WACC: 7.2% × 89.0% + 3.4% × (1 − 25.5%) × 11.0% = 6.64%
termsCost of equity · Equity weight (E/(D+E)) · Cost of debt · (1 − tax rate) · Debt weight (D/(D+E)) · Market capitalization
How firm is this? With the equity risk premium ±1 point and beta ±0.2, WACC runs 5.5%–8.2% and ROIC − WACC runs +21.4 to +24.0 points. The sign holds across this range. This describes the latest year and does not predict future value creation.
WACC 6.64% is this site’s estimate under the assumptions below (not a figure the company has published)
- Risk-free rate
- 4.95% (10-year Treasury, 2026-11-03)
- β
- 0.40 (price-derived adjusted beta, but correlation with the market is low (R² 0.01), so reliability is limited)
- Equity risk premium
- 5.5%
- Cost of equity
- 7.15%
- Cost of debt
- 3.41%
- Tax rate
- 25.5% (effective rate, FY2023–FY2025)
- Capital structure (equity : debt)
- 89% : 11%
ROIC over time, vs. WACC
Unit: % — bars = each period's ROIC, horizontal line = latest WACC. Bars above the line are green, below are red
- ROIC (above WACC)
- ROIC (below WACC)
- WACC 6.64%
formulaoperating income × (1 − tax rate) ÷ invested capital × 100 *invested capital = interest-bearing debt + total equity (average of beginning/ending)
termsOperating income · Effective tax rate · Invested capital · Interest-bearing debt · Total equity
formulacost of equity × equity weight + cost of debt × (1 − tax rate) × debt weight
termsCost of equity · Equity weight (E/(D+E)) · Cost of debt · (1 − tax rate) · Debt weight (D/(D+E)) · Market capitalization
Try different WACC assumptions
β and the equity risk premium are estimates with a real range of plausible values — move the sliders to check whether ROIC > WACC still holds. The risk-free rate starts at the 10-year Treasury yield on 2026-11-03 (U.S. Treasury).
Initial β: 0.40 (price-derived adjusted beta. Raw β 0.11, R² 0.01, 130 weeks)
formula0.67 × β + 0.33 (β = the slope of weekly stock returns regressed on weekly market returns)
e.g.0.67 × 0.107 + 0.33 = 0.402
termsβ (beta)
Period 2024-05-10–2026-11-04, using S&P 500 ETF (SPY) as the market proxy. Source: Yahoo Finance price history.
formularisk-free rate + β × equity risk premium
e.g.5.0% + 0.4 × 5.5% = 7.2%
termsCAPM · Risk-free rate · β (beta) · Equity risk premium (market risk premium)
formulafiscal year-end closing price × shares outstanding (= market cap)
formulainterest expense ÷ interest-bearing debt × 100 (clamped to 0–10%; falls back to the risk-free rate if there’s no debt)
16
What the price implies (DCF)From SEC data
A company's value can be written as its free cash flow divided by (cost of capital − perpetual growth). Working that backwards from the market's valuation shows how much growth the share price assumed — compared here with the company's actual past growth.
Growth the price implies (price on 2026-11-04)
2.4%
Perpetual FCF growth: g = r − FCF ÷ EV = 6.6% − 4.3%
Past FCF growth (FY2020–FY2025)
+1.9%
Compound annual rate, 5 years
Past revenue growth (FY2020–FY2025)
+4.4%
Compound annual rate, 5 years
Inputs (FY2025): free cash flow $3.63B (operating CF − capex); enterprise value $85.12B = market cap $78.67B (latest close, 2026-11-04) + debt $7.84B − cash and short-term investments $1.4B; r = WACC of 6.6% using this page’s default assumptions (β 0.40, risk-free 5.0%, market premium 5.5%).
Three WACC scenarios
The same calculation under cautious, base and optimistic cost-of-capital assumptions (risk-free rate fixed at the 10-year Treasury yield). Pick one to load it into the sliders below.
Try your own assumptions
V = FCF ÷ (r − g). It starts at the implied growth rate, where the theoretical value equals today’s enterprise value.
Theoretical enterprise value
$86.52B
FCF $3.63B ÷ (6.6% − 2.4%)
Theoretical ÷ actual enterprise value
1.02x
Above 1x: these assumptions value the business above the market did
How sensitive the answer is
Theoretical ÷ actual enterprise value for each combination of r and g.
| g \ r | 4.6% | 5.6% | 6.6% | 7.6% | 8.6% |
|---|---|---|---|---|---|
| 0% | 0.93x | 0.76x | 0.65x | 0.56x | 0.50x |
| 2% | 1.64x | 1.19x | 0.93x | 0.76x | 0.65x |
| 4% | 7.12x | 2.67x | 1.64x | 1.19x | 0.93x |
| 6% | — | — | 7.12x | 2.67x | 1.64x |
| 8% | — | — | — | — | 7.12x |
A simplified model for seeing what the market price assumes, not a forecast or a target price. It treats free cash flow as growing at one constant rate forever; the result swings widely with small changes in r and g, and is undefined when g reaches r. Free cash flow here is operating cash flow minus capex, which is after interest — a full DCF of enterprise value would use cash flow before interest. Market cap uses the latest close (2026-11-04) × shares at fiscal year-end; free cash flow and WACC inputs are from the latest fiscal year.
17
Earnings qualityFrom SEC dataShow
The same reported profit can mean different things depending on whether it's backed by cash, driven by the core business, or the result of a one-off item. Four checks below.
- ✓
Operating CF ÷ net income: averages 1.56x
Profit is backed by cash coming in.
- ✓
Accrual ratio (latest): -12.8%
A small share of profit rests on accounting estimates.
- ✓
Core-earnings share (operating income ÷ pretax income): 108%
Most profit comes from core operations.
- ✓
Days sales outstanding: 28 → 29 days
No major slowdown in collecting on sales.
Operating CF vs. net income
Unit: $M — operating CF above net income means profit is backed by cash
- Operating CF
- Net income
formulacash flow from operations ÷ net income attributable to the company
termsCash flow from operations (operating CF) · Net income (attributable to the company)
formula(net income − operating CF) ÷ average total assets × 100
termsNet income (attributable to the company) · Cash flow from operations (operating CF) · Total assets
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-23
Profit bridge (FY2025)
Unit: $M — what moved profit from operating income to net income
- Profit (each stage)
- Pushed profit up
- Pushed profit down
formulaoperating income ÷ income before income taxes × 100
termsOperating income · Income before income taxes (pretax income)
Source: each period's Form 10-K (SEC EDGAR). Latest: filed 2026-02-23
Receivables & inventory days
Unit: days — days grow when receivables or inventory build up faster than sales
- Days sales outstanding
- Days inventory outstanding
formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365
formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365
termsInventory · Cost of revenue (COGS)
Worked examples (latest period)
formulacash flow from operations ÷ net income attributable to the company
e.g.$4,198M ÷ $2,132M = 1.97x
termsCash flow from operations (operating CF) · Net income (attributable to the company)
formulaoperating income ÷ income before income taxes × 100
e.g.$3,306M ÷ $3,059M × 100 = 108%
termsOperating income · Income before income taxes (pretax income)
formulaaverage receivables (opening + closing ÷ 2) ÷ revenue × 365
e.g.($1,521M + $1,675M) ÷ 2 ÷ $20,382M × 365 = 29 days
formulaaverage inventory (opening + closing ÷ 2) ÷ cost of revenue × 365
e.g.($1,987M + $2,032M) ÷ 2 ÷ $8,131M × 365 = 90 days
termsInventory · Cost of revenue (COGS)
18
Who holds the sharesFrom SEC dataShow
How much of the stock large institutional investors report owning on SEC Form 13F, how much the directors and executive officers hold (and how much of the vote they control), and roughly how much is left for individual investors. Shown next to beta so the holder mix can be read alongside how much the stock swings.
Institutions, insiders and everyone else, 13F holdings as of 2026-06-30
“Everyone else” is what remains after shares reported on Form 13F and shares held by directors and executive officers: mostly individual investors, plus non-insider families or foundations and smaller or foreign institutions. The figures have different dates and 13F reports count some shares twice — read it as an approximate split.
- Held by 13F filers
- 85.4%
- Directors & officers (shares)
- <1%
- Everyone else (est.)
- 14.6%
- Directors & officers (voting power)
- <1%
- Institutional-ownership rank
- 260 of 416
- Beta (adjusted)
- 0.40
individuals and other non-13F holders
no separate voting figure; shown as shares
1 = most institutional; 62% of covered companies have more
above 1 = swings more than the market
- 680.6M shares reported by 2,014 13F filers ÷ 797.2M shares outstanding on 2026-06-30. Option positions are excluded.
- Directors and executive officers as a group, from the proxy statement’s beneficial-ownership table (percentage computed from the group’s share count ÷ shares outstanding); includes shares they can acquire within 60 days.
- A large “everyone else” share can still reflect a family, trust or foundation stake held outside the board; check the proxy statement’s 5% holders.
Sources: SEC Form 13F data set (holdings as of 2026-06-30) · Form DEF 14A filed 2026-03-25 (beneficial ownership table) · Form 10-Q cover page (shares outstanding as of 2026-06-30)
19
Strengths & weaknessesSite analysis
Strengths
1. Oral care leadership
Global toothpaste share was 41.4% and manual toothbrush share 33.1% year to date through Q3 2026.
Evidence: 8-K filed 2026-10-30 (Exhibit 99)
2. Emerging market reach
About two-thirds of revenue comes from outside the U.S., and Latin America is its most profitable region.
Evidence: Form 10-K (FY2025) Item 1 and Note 14
3. Strong cash flow
Operating cash flow was $4.20B in 2025, funding $1.82B of dividends.
Evidence: SEC EDGAR XBRL; Form 10-K (FY2025) MD&A
4. Margin gains
Gross margin rose 140 basis points to 61.5% in Q2 2026 and 80 basis points to 60.2% in Q3 2026.
Evidence: 8-K filed 2026-07-31 (Exhibit 99); 8-K filed 2026-10-30 (Exhibit 99)
Weaknesses
1. Skin health write-down
Net income fell to $2.13B from $2.89B in 2025, a year with $919M of goodwill and intangible impairments, mainly on Filorga, after weaker skin health performance, particularly in China.
Evidence: Form 10-K (FY2025) Note 14 and MD&A
2. Slow organic growth
Organic sales grew 1.4% in 2025, with North America and Asia Pacific declining.
Evidence: Form 10-K (FY2025) MD&A
3. Thin equity
Years of buybacks and dividends left Colgate shareholders' equity at just $54M (total equity $365M) at year-end 2025.
Evidence: SEC EDGAR XBRL
20
What draws investors to itSite analysis
Why the stock can look attractive to investors — each point paired with what has to hold for it to stay true, and the opposing view. This is this site's analysis, not a recommendation to buy or sell.
P/E (FY2025)
30.1x
Price at fiscal year-end ÷ diluted EPS
Dividend yield (FY2025)
2.61%
Dividends per share ÷ fiscal year-end price
Payout ratio (FY2025)
78%
Dividends per share ÷ diluted EPS
FCF yield (FY2025)
5.7%
(Operating CF − capex) ÷ market cap
1. Steady dividend
Dividends paid rose from $1.98 per share (2024) to $2.06 (2025); the quarterly dividend is $0.52.
- What has to hold
- Cash flow stays strong.
- The other side
- Equity is thin after years of payouts and buybacks.
Evidence: Form 10-K (FY2025) MD&A
2. Defensive categories
Toothpaste, soap, and pet food are everyday purchases.
- What has to hold
- Brands keep pricing power.
- The other side
- Organic growth slowed to 1.4% in 2025.
Evidence: Form 10-K (FY2025) MD&A
P/E, dividend yield, payout ratio, and FCF yield use the FY2025 year-end share price. Dividends per share for 2024–2025 are amounts paid; 2024 declarations included five quarterly dividends ($2.48).
21
ResilienceSite analysisShow
How well the company could absorb a bad year: its financial buffer, how its revenue and profit held up in the worst year on record, and what the 10-K says about the business's exposure to shocks. Figures and filing statements only — no overall rating.
1. Financial buffer (FY2025)
Cash & short-term investments ÷ debt due within a year
1.3x
$1.4B vs. $1.12B
Interest coverage (operating income ÷ interest expense)
12.4x
$3.31B vs. $267M
Free cash flow ÷ dividends paid
2.0x
$3.63B vs. $1.82B (FCF = operating CF − capex)
2. Worst year in the record, and the recovery
| Figure | Worst year-over-year change | Back to the prior level? |
|---|---|---|
| Revenue | No decline in the record | — |
| Operating income | -22.5% in FY2025 ($4.27B → $3.31B) | Not yet, as of FY2025 |
Covers only the 6 fiscal years on record (FY2020–FY2025), which may not include a full recession — the worst year here isn’t necessarily how the company would fare in a severe downturn.
3. Business resilience (from the 10-K)
Global spread
About 33,600 employees in over 100 countries; five regional OPHC divisions plus Hill's.
Source: Form 10-K (FY2025), Item 1
Cash generation
$4.20B of operating cash flow in 2025.
Source: SEC EDGAR XBRL
22
Legal & regulatory mattersSite analysisShow
Lawsuits, government investigations, enforcement actions and settlements the company discloses — where each stands, what is at stake, and what comes next. From the 10-K's Legal Proceedings and contingencies note, the latest 10-Q, and 8-Ks.
Colgate's open matters are Brazilian tax disputes tied to its 1995 Kolynos acquisition and a growing number of talc lawsuits (561 cases at September 30, 2026). Its $332 million pension ERISA settlement received final approval in January 2026. Colgate estimates reasonably possible losses above accruals at $0 to about $225 million.
2 open matters · 1 settled or closed
Talcum powder lawsuits
PendingProduct liabilityPlaintiffs in U.S. state and federal courts
The suits allege Colgate talc products contained asbestos or caused mesothelioma and other cancers. There were 561 cases at September 30, 2026, up from 525 at June 30 and 453 at year-end 2025; 236 new cases were filed and 128 resolved in the first nine months. Insurance covers part of the costs.
Source: Form 10-Q (quarter ended 2026-09-30) — Legal Proceedings
Brazil Kolynos acquisition tax disputes
PendingTax disputeBrazilian internal revenue authority; Brazilian Federal Public Attorney
The authority disallowed interest and FX deductions tied to financing the 1995 Kolynos acquisition. In December 2025 an appeals court ruled against Colgate in one case (about $19 million), and Colgate's further appeals were denied in August and October 2026; it has appealed again. A separate 2002 suit seeks to make Colgate liable for the seller's capital-gains tax, and a 2005 FX-transaction assessment is about $28 million.
- Amounts
- Kolynos-related assessments about $105 million; Colgate believes it will more likely than not prevail.
Source: Form 10-Q (quarter ended 2026-09-30) — Legal Proceedings
Retirement plan ERISA litigation
SettledClass actionRetirement Plan participants (S.D.N.Y.)
Alleged miscalculation of residual annuity payments from a 2005 plan amendment. Final approval was granted January 2026, and $99 million went to plaintiffs' attorneys, paid by Colgate.
- Amounts
- $332 million settlement, mostly funded by the plan.
Source: Form 10-Q (quarter ended 2026-09-30) — Legal Proceedings
Company statement: Management does not believe these matters will have a material effect on its financial position or ongoing results, though an adverse outcome could be material in a given period.
Based on Form 10-Q (quarter ended 2026-09-30) — Legal Proceedings, reviewed 2026-10-18. Routine ordinary-course claims are not listed. “Major” is this site’s judgment of which matters could materially affect results.
23
Risks (including geopolitical)Site analysis
Starting from the 10-K's Risk Factors section, organized by category — geopolitical, currency, raw materials, regulatory, disaster, and more — with impact and likelihood assessed by this site.
Risk map
Vertical = impact on results, horizontal = likelihood. Upper right = most severe. Numbers match the list below (placement is this site’s own assessment).
Likelihood →
"Company disclosure" vs. "this site’s assessment"
The description and mitigation for each risk are this site’s summary of the 10-K’s "Risk Factors" section. Impact and likelihood are this site’s own assessment, not the company’s — where the company discloses its own likelihood assessment, that is noted in the summary.
Impact is judged from how large the affected business is relative to total revenue/profit, and from the risk’s track record of moving results in the past. Likelihood is judged from the filing’s wording and the current business environment (already occurring, or recurring). See the rating criteria.
- 1Competition & technology shift
Competition and retailer power
- Company disclosure (summarized from the 10-K)
- Multinational and local competitors, private label, and direct-to-consumer brands compete for shelf and attention; key retailers have greater bargaining strength and control consumer data.
- Company’s stated mitigation
- Advertising investment, innovation, and omni-channel demand generation.
- This site’s assessment
- Impact Med / Likelihood High
- 2FX & interest rates
Currency
- Company disclosure (summarized from the 10-K)
- About two-thirds of revenue is outside the U.S., so a stronger dollar reduces reported sales (−5.2% FX impact on OPHC sales in 2024).
- Company’s stated mitigation
- In an effort to minimize the impact on earnings of foreign currency rate movements, we engage in a combination of selling price increases, where permitted, sourcing strategies, cost containment measures and selective hedging of foreign currency transactions.
- This site’s assessment
- Impact Med / Likelihood High
- 3Costs & inflation
Commodity costs
- Company disclosure (summarized from the 10-K)
- Higher raw and packaging material costs may not be fully offset.
- Company’s stated mitigation
- Pricing, sourcing strategies, productivity initiatives, and limited commodity hedging.
- This site’s assessment
- Impact Med / Likelihood Med
- 4M&A & integration
Acquisition impairments
- Company disclosure (summarized from the 10-K)
- Acquired brands such as Filorga have been written down.
- Company’s stated mitigation
- Not stated in the filings.
- This site’s assessment
- Impact Med / Likelihood Med
- 5Law & regulation
Litigation
- Company disclosure (summarized from the 10-K)
- An ERISA pension lawsuit led to $99M of charges in 2025.
- Company’s stated mitigation
- Not stated in the filings.
- This site’s assessment
- Impact Low / Likelihood Med
24
What changed in the risk factorsFrom SEC data
Paragraphs in the latest 10-K's Risk Factors that have little overlap with the year before, and paragraphs that were dropped.
New or substantially reworded (5)
Uncertainties and risks remain as to the evolving situation in Venezuela. Read more
We have operations, including a manufacturing facility, in Venezuela; however, since December 31, 2015, the local operating results from our Venezuela operations have not been included in our Consolidated Financial Statements. Nonetheless, the situation in Venezuela could have ramifications for our business in Venezuela and the broader Latin American region and on geopolitical relations more generally. The situation may impact consumer sentiment and consumption and category growth rates in the Latin American region, supply chain and logistics, and the availability and cost of raw and packaging materials and commodities, such as oil.
Major developments in trade relations, including the imposition of new or increased tariffs by the United States and/or other countries, such as China, including those threatened or imposed following the United States’ 2025 executive orders, retaliatory tariffs imposed by the United States’ trading partners or through the renegotiation of trade agreements, have contributed to and are expected to continue to contribute to inflationary pressures, geopolitical tensions, macroeconomic and market volatility and consumer uncertainty. These developments have also impacted and may continue to impact consumer sentiment, consumption, discretionary spending and/or purchasing patterns. In addition, they have impacted and may continue to impact the cost and/or availability of raw and packaging materials and the price of our products. While we have made and will continue to make efforts to mitigate…
• governmental incentives, regulations and controls and actual and potential shifts in U.S. Read more
and foreign trade policy (including import restrictions and export controls, new or increased tariffs, new or revised trade agreements, sanctions, quotas, trade barriers or new or increased regulations related to Good Manufacturing Practices); and
We may not realize the benefits that we expect from our Strategic Growth and Productivity Program.
Uncertain or unfavorable global macroeconomic and geopolitical conditions may adversely affect our business.
No longer in the text (4)
The conflict in the Middle East has not had a material impact on our Consolidated Financial Statements. Read more
Uncertainties and risks remain as to the duration of the conflict and its impact on geopolitical relations and stability in North Africa, the wider Middle East and nearby regions. The conflict has impacted and may continue to impact, among other things, supply chain and logistics, the availability and price of raw and packaging materials and commodities, such as oil, consumer sentiment and consumption and category growth rates in the region.
Furthermore, the imposition of tariffs and/or increases in tariffs on various raw materials or products, or threats to impose or increase such tariffs, by the United States and other countries have introduced greater uncertainty with respect to trade policies and government regulations affecting trade between the United States and other countries and new and/or increased tariffs have subjected, and may continue in the future to subject, us to additional costs and expenditure of resources. Major developments in trade relations, including the imposition of new or increased tariffs by the United States and/or other countries, such as China, Mexico and Canada, including those imposed following the United States’ February 2025 executive orders, and any nationalist trends in specific countries, have altered and could continue to alter the trade environment and consumer purchasing behavior…
Further, the retail landscape in many of our markets continues to evolve as a result of the substantial growth of eCommerce, changing consumer behaviors and preferences (as consumers increasingly shop online, including to compare prices and product availability) and the increased presence of alternative retail channels, such as subscription services and direct-to-customer businesses. The substantial growth in eCommerce and the emergence of alternative retail channels have created and may continue to create pricing pressures and/or adversely affect our relationships with our key retailers.
In addition, consumer preferences continue to evolve due to a number of factors, including evolving consumer concerns or perceptions (whether or not valid) regarding sustainability and social impact practices, including the sourcing and sustainability of raw and packaging materials, a demand for natural or organic products and ingredients and ingredient transparency, consumer concerns or perceptions regarding the effects of ingredients, consumer sentiment toward non-local products or sources and perceptions of and increased focus on labor and human rights and environmental impacts (including responsible sourcing, deforestation, packaging, plastic, energy and water use and waste management).
1 more paragraphs differ; the filings below have the full text.
Matched automatically, quoted as filed, and may include rewording of an existing risk. Compares Item 1A of the 10-K filed Feb 23, 2026 ↗ with the 10-K filed Feb 13, 2025 ↗.
25
What to watch going forwardSite analysis
- Results under the new EMEA segment structure.
- Savings from the expanded Strategic Growth and Productivity Program.
- Hill's growth and private label pet food volumes.
- Currency effects in Latin America.
- Skin health portfolio performance after the impairment.
26
Source documentsShow
This page's financial figures come from the Form 10-Ks listed below. Check the original filings for full detail.
Last updated
Analysis last edited: November 6, 2026 · Financial data fetched: October 17, 2026 10:06 (SEC EDGAR) · Source 10-K filed: February 23, 2026
Built on10-K FY2025 · filed 2026-02-23
Next update expectedAfter FY2026’s 10-K is filed (roughly 60–90 days after fiscal year end (sooner for larger filers)), financials and analysis will be refreshed.
This page is this site’s own analysis based on public information, and does not represent Colgate-Palmolive’s views. It is not a recommendation to buy or sell any security, and this site does not guarantee the accuracy of any figure or statement here. Always verify against the original source documents before making an investment decision.